Iovance Biotherapeutics, Inc. IOVA

11.00 0.20 1.85% as of 25 Sep
Market cap
$4.9B
P/E
0.0×

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
296.98 323.78 279.87 471.85 504.41 629.44 307.08 468.52 145.37 166.47
Receivables
82.45 69.34 0.15 — — — — — — —
Inventory
51.68 51.52 10.37 — — — — — — —
Total current assets
442.69 457.02 307.85 479.12 507.96 636.10 316.49 475.37 149.29 169.51
Property, Plant, Equpment (Net)
131.11 109.08 114.03 105.23 100.94 59.16 8.54 2.68 2.45 2.37
Long-Term Investments
— — — — 91.59 — — — — —
Goodwill and Intangible Assets (Total)
279.32 282.40 229.26 — — — — — — —
Long-term assets (Other)
14.15 6.73 66.70 6.62 7.87 18.44 8.93 2.76 3.63 —
Total non-current assets
470.48 453.41 472.50 184.87 269.38 132.36 28.16 5.45 6.08 2.37
Total Assets
913.17 910.43 780.35 663.98 777.33 768.46 344.66 480.82 155.37 171.89
Notes Payable
1.00 — — — — — — — — —
Accounts Payable
22.16 27.51 33.12 26.60 27.38 13.51 15.57 2.74 1.23 0.86
Accrued Expenses
111.16 81.94 69.41 52.30 56.77 35.07 16.27 11.66 8.36 4.11
Total current liabilities
138.36 122.34 110.31 91.49 89.20 54.87 39.08 14.40 9.60 4.97
Long Term Debt (Total)
— 1.00 1.00 1.00 1.00 — 4.25 — — —
Non-current Revenue (Deferred)
— — — — — — — 0.23 0.30 —
Long Term Tax Liability (Deferred)
31.83 32.32 17.35 — — — — — — —
Non-current Liabilities (Other)
— — — — — 11.71 2.35 0.23 — —
Total non-current liabilities
76.23 77.68 85.43 72.86 66.47 57.09 6.60 0.23 0.30 —
Total liabilities
214.59 200.02 195.74 164.34 155.67 111.96 45.68 14.63 9.89 4.97
Additional Paid In Capital
3,457.65 3,095.99 2,594.45 2,068.87 1,794.70 1,486.66 869.35 838.98 394.65 323.99
Preferred Stock (Total)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01
Common Stock (Net)
0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00
Retained Earnings
(2,775.53) (2,384.55) (2,012.37) (1,568.34) (1,172.44) (830.19) (570.61) (372.76) (249.18) (157.12)
Common Equity (Total)
698.58 710.40 584.61 499.64 621.66 656.49 298.97 466.19 145.47 166.91
Shareholders Equity (Total)
698.58 710.41 584.61 499.64 621.66 656.50 298.97 466.19 145.48 166.92
Shareholders Equity and Liabilities (Total)
913.17 910.43 780.35 663.98 777.33 768.46 344.66 480.82 155.37 171.89
Shares (Common)
411.94 305.25 256.14 187.81 157.01 146.88 126.41 123.42 73.17 62.25
Shares (Preferred)
1.93 2.84 2.84 2.84 2.84 3.58 3.58 5.86 7.38 7.95
Shareholders Equity (Tangible)
419.26 428.01 355.36 499.64 621.66 656.50 298.97 466.19 145.48 166.92
Net Debt
(296.98) (322.78) (278.87) (470.84) (503.41) (629.44) (302.83) (468.52) (145.37) (166.47)
Total Debt
— 1.00 1.00 1.00 1.00 — 4.25 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates